{ "cells": [ { "cell_type": "code", "execution_count": 86, "metadata": {}, "outputs": [], "source": [ "from sentence_transformers import SentenceTransformer, util\n", "import pandas as pd\n", "import re" ] }, { "cell_type": "code", "execution_count": 87, "metadata": {}, "outputs": [], "source": [ "# Target列を分割する関数\n", "def split_target(target):\n", " # 指定された区切り文字で分割\n", " split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n", " # 空白文字を除外してリストとして返す\n", " return [word.strip() for word in split_words if word.strip()]" ] }, { "cell_type": "code", "execution_count": 88, "metadata": {}, "outputs": [], "source": [ "basedf = pd.read_csv('../ClinicalTrialCSV/JRCT20241202Cancer.csv', index_col=0)\n", "basedf = basedf.dropna(subset=['試験等のフェーズ'])\n", "# Target列を分割してTargetWord列を追加\n", "basedf['TargetWord'] = basedf['Target'].apply(split_target)" ] }, { "cell_type": "code", "execution_count": 84, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTarget研究・治験の目的試験等のフェーズ試験の種類無作為化盲検化...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWord
0jRCT2021240039NCT06632951NaN[M25-204]転移性尿路上皮癌患者を対象に，livmoniplimab とbudigal...尿路上皮癌主要目的：全生存期間（以下「OS」）を指標として，livmoniplimab と budig...2NaN無作為化比較非盲検...treatment purpose-Participant has histologically or cytological...-Participant has received more than 1 prior ch...18age old overNo limitBothNaNNaN-Arm 1: Livmoniplimab (Dose A) + Budigalimab\\r...[尿路上皮癌]
4jRCT2031240512NaNNaNフッ化ピリミジン製剤及びプラチナ製剤を含む一次治療に不応・不耐となった切除不能進行・再発胃癌...切除不能進行・再発胃癌フッ化ピリミジン・プラチナ系薬剤に不応・不耐の切除不能進行・再発胃癌被験者を対象として、ベバ...1NaN無作為化比較非盲検...treatment purpose1)\\tAge between 18 and 75 years.\\r\\n2)\\tPerfor...1)\\tPrior treatment history with paclitaxel, r...18age old over75age old underBothNaNNaNSafety Part (Dose Escalation):\\r\\nLevel 0: Bev...[切除不能進行, 再発胃癌]
7jRCT2051240197NCT06692738NaNPD-L1 陽性の転移性扁平上皮非小細胞肺癌患者に対する一次治療として、Rilvegosto...非小細胞肺癌Treatment3NaN無作為化比較二重盲検...treatment purpose- Histologically or cytologically documented s...- Presence of small cell and neuroendocrine hi...18age old overNo limitBothNaNNaNParticipants will be randomized in a 1:1 ratio...[非小細胞肺癌]
8jRCT2031240508NCT06573294NaN悪性固形癌患者を対象にGEN1057の安全性及び抗腫瘍活性を評価するヒト初回投与、非盲検、用...進行性悪性固形癌\\n転移性悪性固形癌本第I相試験の目的は、転移性又は進行性病変を有する悪性固形癌患者を対象に、GEN1057を単...1NaN単一群非盲検...treatment purpose-Advanced and/or metastatic solid tumors, who ...Has been exposed to any of the following prior...18age old overNo limitBothNaNNaNGEN1057 monotherapy will be administered intra...[進行性悪性固形癌, 転移性悪性固形癌]
12jRCT2041240130NaNNaN中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...肺がん全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...2NaN無作為化比較非盲検...treatment purpose(1) Patients scheduled to undergo anatomical l...(1) Patients with a history of allergy to the ...18age old overNo limitBothNaNNaNTreatment group\\r\\nAdminister GRA 1mg intraven...[肺がん]
..................................................................
974jRCT2031200203NCT04379596NaNHER2発現の成人胃癌患者を対象としてトラスツズマブ デルクステカン（T-DXd）の単剤療法...胃腺癌、胃食道接合部腺癌又は食道腺癌DESTINY-Gastric03は、HER2発現の進行・転移性胃癌・胃食道接合部（GEJ）...1-2NaN無作為化比較非盲検...treatment purpose1. Male and female participants must be at lea...1. History of active primary immunodeficiency,...18age old over130age old underBothNaNNaNExperimental: Arm 1A: T-DXd and 5-fluorouracil...[胃腺癌, 胃食道接合部腺癌, 食道腺癌]
981jRCT2031200153NaNNaNCellm-001による初発膠芽腫治療効果無作為比較対照試験膠芽腫脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...3NaN無作為化比較二重盲検...treatment purpose(1) 18 years old or older and 75 years old or ...(1) Systemic administration of corticosteroids...18age old over75age old underBothNaNNaNInject the investigational drug (Cellm-001 or ...[膠芽腫]
996jRCT2031200087NaNNaN4型進行胃癌に対する術後または周術期補助化学療法としての全身・腹腔内併用化学療法と全身化学療...4型進行胃癌術後腹膜播種のリスクが高い4型進行胃癌を対象として、全身・腹腔内併用化学療法の全身化学療法に...3NaN無作為化比較非盲検...treatment purposeConfirmation before temporary registration\\r\\n...1)\\tSimultaneously active double cancer.\\r\\n2)...20age old over75age old underBothNaNNaNS-1 monotherapy\\r\\noral S-1 80 mg/m2/day on da...[4型進行胃癌]
1053jRCT2033190086NaNNaN悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...悪性黒色腫第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...1-2NaN単一群非盲検...treatment purpose(Phase 1)\\r\\n1) Histologically confirmed malig...(Phase 1 and 2)\\r\\n1) Patients who have brain ...20age old overNo limitBothNaNmalignamt melanoma, advanced stageTest drug (T-hIL12) will be administered into ...[悪性黒色腫]
1067jRCT2051190009NCT03818893JapicCTI-194618進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...進行性悪性黒色腫抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...1-2NaN非無作為化比較非盲検...treatment purposeInclusion criteria \\r\\nPatients meeting all of...Exclusion criteria\\r\\nPatients meeting any of ...20age old over86age old notBothNaNadvanced melanomacombination therapy of intracutaneous GEN0101 ...[進行性悪性黒色腫]
\n", "

416 rows × 39 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "0 jRCT2021240039 NCT06632951 NaN \n", "4 jRCT2031240512 NaN NaN \n", "7 jRCT2051240197 NCT06692738 NaN \n", "8 jRCT2031240508 NCT06573294 NaN \n", "12 jRCT2041240130 NaN NaN \n", "... ... ... ... \n", "974 jRCT2031200203 NCT04379596 NaN \n", "981 jRCT2031200153 NaN NaN \n", "996 jRCT2031200087 NaN NaN \n", "1053 jRCT2033190086 NaN NaN \n", "1067 jRCT2051190009 NCT03818893 JapicCTI-194618 \n", "\n", " Title Target \\\n", "0 [M25-204]転移性尿路上皮癌患者を対象に，livmoniplimab とbudigal... 尿路上皮癌 \n", "4 フッ化ピリミジン製剤及びプラチナ製剤を含む一次治療に不応・不耐となった切除不能進行・再発胃癌... 切除不能進行・再発胃癌 \n", "7 PD-L1 陽性の転移性扁平上皮非小細胞肺癌患者に対する一次治療として、Rilvegosto... 非小細胞肺癌 \n", "8 悪性固形癌患者を対象にGEN1057の安全性及び抗腫瘍活性を評価するヒト初回投与、非盲検、用... 進行性悪性固形癌\\n転移性悪性固形癌 \n", "12 中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr... 肺がん \n", "... ... ... \n", "974 HER2発現の成人胃癌患者を対象としてトラスツズマブ デルクステカン（T-DXd）の単剤療法... 胃腺癌、胃食道接合部腺癌又は食道腺癌 \n", "981 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 膠芽腫 \n", "996 4型進行胃癌に対する術後または周術期補助化学療法としての全身・腹腔内併用化学療法と全身化学療... 4型進行胃癌 \n", "1053 悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第... 悪性黒色腫 \n", "1067 進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体... 進行性悪性黒色腫 \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 \\\n", "0 主要目的：全生存期間（以下「OS」）を指標として，livmoniplimab と budig... 2 NaN \n", "4 フッ化ピリミジン・プラチナ系薬剤に不応・不耐の切除不能進行・再発胃癌被験者を対象として、ベバ... 1 NaN \n", "7 Treatment 3 NaN \n", "8 本第I相試験の目的は、転移性又は進行性病変を有する悪性固形癌患者を対象に、GEN1057を単... 1 NaN \n", "12 全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro... 2 NaN \n", "... ... ... ... \n", "974 DESTINY-Gastric03は、HER2発現の進行・転移性胃癌・胃食道接合部（GEJ）... 1-2 NaN \n", "981 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... 3 NaN \n", "996 術後腹膜播種のリスクが高い4型進行胃癌を対象として、全身・腹腔内併用化学療法の全身化学療法に... 3 NaN \n", "1053 第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ... 1-2 NaN \n", "1067 抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010... 1-2 NaN \n", "\n", " 無作為化 盲検化 ... purpose \\\n", "0 無作為化比較 非盲検 ... treatment purpose \n", "4 無作為化比較 非盲検 ... treatment purpose \n", "7 無作為化比較 二重盲検 ... treatment purpose \n", "8 単一群 非盲検 ... treatment purpose \n", "12 無作為化比較 非盲検 ... treatment purpose \n", "... ... ... ... ... \n", "974 無作為化比較 非盲検 ... treatment purpose \n", "981 無作為化比較 二重盲検 ... treatment purpose \n", "996 無作為化比較 非盲検 ... treatment purpose \n", "1053 単一群 非盲検 ... treatment purpose \n", "1067 非無作為化比較 非盲検 ... treatment purpose \n", "\n", " Inclusion Criteria \\\n", "0 -Participant has histologically or cytological... \n", "4 1)\\tAge between 18 and 75 years.\\r\\n2)\\tPerfor... \n", "7 - Histologically or cytologically documented s... \n", "8 -Advanced and/or metastatic solid tumors, who ... \n", "12 (1) Patients scheduled to undergo anatomical l... \n", "... ... \n", "974 1. Male and female participants must be at lea... \n", "981 (1) 18 years old or older and 75 years old or ... \n", "996 Confirmation before temporary registration\\r\\n... \n", "1053 (Phase 1)\\r\\n1) Histologically confirmed malig... \n", "1067 Inclusion criteria \\r\\nPatients meeting all of... \n", "\n", " Exclusion Criteria Age Minimum \\\n", "0 -Participant has received more than 1 prior ch... 18age old over \n", "4 1)\\tPrior treatment history with paclitaxel, r... 18age old over \n", "7 - Presence of small cell and neuroendocrine hi... 18age old over \n", "8 Has been exposed to any of the following prior... 18age old over \n", "12 (1) Patients with a history of allergy to the ... 18age old over \n", "... ... ... \n", "974 1. History of active primary immunodeficiency,... 18age old over \n", "981 (1) Systemic administration of corticosteroids... 18age old over \n", "996 1)\\tSimultaneously active double cancer.\\r\\n2)... 20age old over \n", "1053 (Phase 1 and 2)\\r\\n1) Patients who have brain ... 20age old over \n", "1067 Exclusion criteria\\r\\nPatients meeting any of ... 20age old over \n", "\n", " Age Maximum Gender Discontinuation Criteria \\\n", "0 No limit Both NaN \n", "4 75age old under Both NaN \n", "7 No limit Both NaN \n", "8 No limit Both NaN \n", "12 No limit Both NaN \n", "... ... ... ... \n", "974 130age old under Both NaN \n", "981 75age old under Both NaN \n", "996 75age old under Both NaN \n", "1053 No limit Both NaN \n", "1067 86age old not Both NaN \n", "\n", " Keyword \\\n", "0 NaN \n", "4 NaN \n", "7 NaN \n", "8 NaN \n", "12 NaN \n", "... ... \n", "974 NaN \n", "981 NaN \n", "996 NaN \n", "1053 malignamt melanoma, advanced stage \n", "1067 advanced melanoma \n", "\n", " Intervention(s) TargetWord \n", "0 -Arm 1: Livmoniplimab (Dose A) + Budigalimab\\r... [尿路上皮癌] \n", "4 Safety Part (Dose Escalation):\\r\\nLevel 0: Bev... [切除不能進行, 再発胃癌] \n", "7 Participants will be randomized in a 1:1 ratio... [非小細胞肺癌] \n", "8 GEN1057 monotherapy will be administered intra... [進行性悪性固形癌, 転移性悪性固形癌] \n", "12 Treatment group\\r\\nAdminister GRA 1mg intraven... [肺がん] \n", "... ... ... \n", "974 Experimental: Arm 1A: T-DXd and 5-fluorouracil... [胃腺癌, 胃食道接合部腺癌, 食道腺癌] \n", "981 Inject the investigational drug (Cellm-001 or ... [膠芽腫] \n", "996 S-1 monotherapy\\r\\noral S-1 80 mg/m2/day on da... [4型進行胃癌] \n", "1053 Test drug (T-hIL12) will be administered into ... [悪性黒色腫] \n", "1067 combination therapy of intracutaneous GEN0101 ... [進行性悪性黒色腫] \n", "\n", "[416 rows x 39 columns]" ] }, "execution_count": 84, "metadata": {}, "output_type": "execute_result" } ], "source": [ "basedf" ] }, { "cell_type": "code", "execution_count": 89, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n", " warnings.warn(\n" ] } ], "source": [ "# クエリ\n", "query = \"乳がん\"\n", "\n", "# モデルのロード\n", "model = SentenceTransformer('all-MiniLM-L6-v2')\n", "\n", "# クエリをベクトル化\n", "query_vec = model.encode(query, convert_to_tensor=True)\n" ] }, { "cell_type": "code", "execution_count": 102, "metadata": {}, "outputs": [], "source": [ "# ターゲットリスト全体を処理\n", "matched_indices = []\n", "target_vecs_list = []\n", "cosine_scores_list = []\n", "for idx, target_words in enumerate(basedf['TargetWord']):\n", " # ターゲット内の各単語をベクトル化\n", " target_vecs = model.encode(target_words, convert_to_tensor=True)\n", " # コサイン類似度を計算\n", " cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()\n", " target_vecs_list.append(target_vecs)\n", " cosine_scores_list.append(cosine_scores)\n", " # 閾値を超えるか確認\n", " if (cosine_scores >= 0.7).any(): # いずれかが閾値を超えている場合\n", " matched_indices.append(idx)\n", "\n", "# 抽出\n", "matched_df = basedf.iloc[matched_indices]" ] }, { "cell_type": "code", "execution_count": 113, "metadata": {}, "outputs": [ { "data": { "text/plain": [ "4" ] }, "execution_count": 113, "metadata": {}, "output_type": "execute_result" } ], "source": [ "matched_indices[0]" ] }, { "cell_type": "code", "execution_count": 115, "metadata": {}, "outputs": [ { "name": "stdout", "output_type": "stream", "text": [ "tensor(1., device='mps:0')\n", "tensor([0.5316, 0.7820, 0.9005, 0.6651, 0.6537], device='mps:0')\n", "tensor(0.7820, device='mps:0')\n", "tensor([0.8813, 0.7659, 0.7375, 0.6654], device='mps:0')\n", "tensor([0.4314, 0.7559], device='mps:0')\n", "tensor(0.7012, device='mps:0')\n", "tensor(0.9683, device='mps:0')\n", "tensor([0.8813, 0.6887, 0.7659], device='mps:0')\n", "tensor(0.7820, device='mps:0')\n", "tensor(0.7820, device='mps:0')\n", "tensor(0.7190, device='mps:0')\n", "tensor(1., device='mps:0')\n", "tensor([0.8813, 0.6887, 0.7659], device='mps:0')\n", "tensor([0.5691, 0.9683], device='mps:0')\n", "tensor([1.0000, 0.5633, 0.8272], device='mps:0')\n", "tensor(0.7820, device='mps:0')\n", "tensor([0.4257, 0.7559], device='mps:0')\n", "tensor([0.6060, 0.8272], device='mps:0')\n", "tensor(0.9683, device='mps:0')\n", "tensor(0.9683, device='mps:0')\n", "tensor([0.4901, 0.7075], device='mps:0')\n", "tensor(0.9683, device='mps:0')\n", "tensor([1.0000, 0.9335], device='mps:0')\n", "tensor(0.7103, device='mps:0')\n", "tensor([0.6060, 0.9335], device='mps:0')\n", "tensor([0.6060, 0.8272, 0.6060, 0.5189, 0.6060, 0.5161], device='mps:0')\n", "tensor([0.7628, 0.4268, 0.1960], device='mps:0')\n", "tensor([0.9683, 0.5335], device='mps:0')\n", "tensor(0.7223, device='mps:0')\n", "tensor([0.5981, 0.4374, 0.4223, 0.5691, 0.9683], device='mps:0')\n", "tensor(0.9683, device='mps:0')\n", "tensor([0.5651, 0.8813], device='mps:0')\n", "tensor([0.9683, 0.4708, 0.5691], device='mps:0')\n", "tensor([0.5039, 0.4994, 0.9005, 0.9683], device='mps:0')\n", "tensor([1.0000, 0.9335], device='mps:0')\n", "tensor(0.9683, device='mps:0')\n", "tensor(0.9683, device='mps:0')\n", "tensor(0.7659, device='mps:0')\n", "tensor([0.5464, 0.8813], device='mps:0')\n", "tensor([0.5633, 1.0000], device='mps:0')\n", "tensor(0.9387, device='mps:0')\n", "tensor([0.6637, 0.5138, 0.9683, 0.4046, 0.4765], device='mps:0')\n", "tensor(0.9683, device='mps:0')\n", "tensor(1., device='mps:0')\n", "tensor(0.9683, device='mps:0')\n", "tensor(0.9683, device='mps:0')\n", "tensor([0.6060, 0.8272], device='mps:0')\n", "tensor(0.9683, device='mps:0')\n", "tensor([0.5651, 0.8813], device='mps:0')\n", "tensor(1., device='mps:0')\n", "tensor([0.7099, 0.7024], device='mps:0')\n", "tensor(0.7820, device='mps:0')\n", "tensor(0.8280, device='mps:0')\n", "tensor([0.9683, 0.8464, 0.0214, 0.1548], device='mps:0')\n", "tensor(0.9683, device='mps:0')\n" ] } ], "source": [ "for n in matched_indices:\n", " print(cosine_scores_list[n])" ] }, { "cell_type": "code", "execution_count": 106, "metadata": {}, "outputs": [ { "name": "stdout", "output_type": "stream", "text": [ "torch.Size([1, 384])\n", "torch.Size([2, 384])\n", "torch.Size([1, 384])\n", "torch.Size([2, 384])\n", "torch.Size([1, 384])\n", "torch.Size([2, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([2, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([2, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([2, 384])\n", "torch.Size([3, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([5, 384])\n", "torch.Size([3, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([2, 384])\n", "torch.Size([2, 384])\n", "torch.Size([4, 384])\n", "torch.Size([1, 384])\n", "torch.Size([4, 384])\n", "torch.Size([3, 384])\n", "torch.Size([2, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([2, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([3, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([4, 384])\n", "torch.Size([1, 384])\n", "torch.Size([2, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([4, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([2, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([5, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([2, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([3, 384])\n", "torch.Size([4, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([3, 384])\n", "torch.Size([2, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([3, 384])\n", "torch.Size([3, 384])\n", "torch.Size([1, 384])\n", "torch.Size([2, 384])\n", "torch.Size([1, 384])\n", "torch.Size([1, 384])\n", "torch.Size([3, 384])\n" ] } ], "source": [ "for i in range(100):\n", " print(target_vecs_list[i].shape)" ] }, { "cell_type": "code", "execution_count": 108, "metadata": {}, "outputs": [ { "name": "stdout", "output_type": "stream", "text": [ "torch.Size([])\n", "torch.Size([2])\n", "torch.Size([])\n", "torch.Size([2])\n", "torch.Size([])\n", "torch.Size([2])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([2])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([2])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([2])\n", "torch.Size([3])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([5])\n", "torch.Size([3])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([2])\n", "torch.Size([2])\n", "torch.Size([4])\n", "torch.Size([])\n", "torch.Size([4])\n", "torch.Size([3])\n", "torch.Size([2])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([2])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([3])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([4])\n", "torch.Size([])\n", "torch.Size([2])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([4])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([2])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([5])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([2])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([3])\n", "torch.Size([4])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([3])\n", "torch.Size([2])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([3])\n", "torch.Size([3])\n", "torch.Size([])\n", "torch.Size([2])\n", "torch.Size([])\n", "torch.Size([])\n", "torch.Size([3])\n" ] } ], "source": [ "for i in range(100):\n", " print(cosine_scores_list[i].shape)" ] }, { "cell_type": "code", "execution_count": 111, "metadata": {}, "outputs": [ { "data": { "text/plain": [ "tensor(0.5400, device='mps:0')" ] }, "execution_count": 111, "metadata": {}, "output_type": "execute_result" } ], "source": [ "cosine_scores_list[0]" ] }, { "cell_type": "code", "execution_count": 85, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n", " warnings.warn(\n" ] } ], "source": [ "# 日本語対応マルチリンガルモデルを使用(例: 'distiluse-base-multilingual-cased-v1')\n", "model_name = 'sentence-transformers/distiluse-base-multilingual-cased-v1'\n", "model = SentenceTransformer(model_name)" ] }, { "cell_type": "code", "execution_count": 50, "metadata": {}, "outputs": [], "source": [ "# クエリ例\n", "query = \"神経膠腫\"\n", "# クエリのベクトル化\n", "query_vec = model.encode(query, convert_to_tensor=True)\n", "\n", "# 全データのターゲット列をベクトル化\n", "target_list = basedf['Target'].tolist()\n", "target_vecs = model.encode(target_list, convert_to_tensor=True)" ] }, { "cell_type": "code", "execution_count": 51, "metadata": {}, "outputs": [], "source": [ "# コサイン類似度を計算\n", "cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()" ] }, { "cell_type": "code", "execution_count": 56, "metadata": {}, "outputs": [], "source": [ "threshold = 0.7\n", "# nonzero()の返り値はタプル (indices_array, ) なので [0] でインデックス配列を取得\n", "matched_indices = (cosine_scores >= threshold).nonzero().tolist()\n", "# 入れ子リストをフラットなリストに変換\n", "flat_indices = [idx[0] for idx in matched_indices]\n", "\n", "# 抽出\n", "matched_df = basedf.iloc[flat_indices]\n" ] }, { "cell_type": "markdown", "metadata": {}, "source": [] }, { "cell_type": "code", "execution_count": 57, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTarget研究・治験の目的試験等のフェーズ試験の種類無作為化盲検化...assignmentpurposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)
67jRCT2051240150NCT06622941NaNONO-4538-126：ラブドイド腫瘍を対象としたONO-4538 の有効性及び安全性を検...ラブドイド腫瘍ラブドイド腫瘍を対象としたONO-4538 の有効性及び安全性を検討する2NaN単一群非盲検...single assignmenttreatment purpose1. Gender: Not specified\\r\\n2. Age (at the tim...1. Patients with a history of active concurren...1age old overNo limitBothNaNNaNFor adults, Nivolumab (recombinant) is adminis...
103jRCT2051240121NCT06413706NaN放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...悪性神経膠腫放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...2NaN無作為化比較非盲検...parallel assignmenttreatment purposeSubjects required to meet all the folloiwng cr...Patients who meets any of the following criter...No limit21age old notNaNNaNNaNDrug: Abemaciclib\\r\\nAdministered orally\\r\\nOt...
224jRCT2031240090NaNNaN再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...悪性神経膠腫再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl...3NaN無作為化比較非盲検...parallel assignmenttreatment purpose1) Histologically diagnosed as high grade glio...1) Have a history or merger of other malignanc...18age old over75age old underBothNaNglioblastoma, grade3/4 astrocytoma, grade3 oli...Group A: BPC Therapy\\r\\nDepending on the patie...
286jRCT2071230124NCT06541665NaNONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40...中枢神経系原発リンパ腫未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及...1NaN単一群非盲検...single assignmenttreatment purpose1. Patients diagnosed with PCNSL\\r\\n2. Patient...1.Patients with intraocular PCNSL without brai...18age old overNo limitBothNaNNaNConcomitant administration of ONO-4059 and rit...
321jRCT2071230114NCT06240741NaN日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを...神経内分泌腫瘍（NEN）神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT...3NaN単一群非盲検...single assignmentdiagnostic purpose1. Signed informed consent must be obtained pr...1. Inability to complete the needed investigat...18age old overNo limitBothNaNNaN[68Ga]Ga-DOTA-TATE will be administered intrav...
338jRCT2041230136NaNNaN再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験再発膠芽腫再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を...1NaN単一群非盲検...single assignmenttreatment purpose(1) Patients with a histological diagnosis of ...(1) Patients with extracerebral metastases.\\r\\...18age old over75age old underBothNaNNaNDosing frequency: 1 time /week\\r\\nDose Levels\\...
349jRCT2032230554NaNNaN初発膠芽腫に対する新型高出力中性子線源を用いた加速器BNCT装置iBNCT001及びSPM-...初発膠芽腫治験機器iBNCT001及び治験薬SPM-011を用いたホウ素中性子捕捉療法（BNCT）に、...1NaN非無作為化比較非盲検...single assignmentother- Karnofsky Performance Status is greater than...- Multiple lesions, bilateral lesions, dissemi...18age old over85age old underBothNaNboron, neutron, glioblastoma- Intravenous administration of investigationa...
473jRCT2051230069NaNNaN神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...神経膠腫神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...1NaN単一群非盲検...single assignmenttreatment purpose<Cohort 1>\\r\\n All of the following items shal...<Common to Cohort 1 and Cohort 2>\\r\\n1) Active...18age old overNo limitBothNaNNaN<cohort1>\\r\\nLomustine 130 mg/m2 orally every ...
476jRCT2021230016NaNNaN皮膚血管肉腫に対するパクリタキセルとTM5614併用の安全性・有効性を検討する第Ⅱ相医師主導治験皮膚血管肉腫皮膚血管肉腫のパクリタキセル単剤療法無効症例を対象にTM5614とパクリタキセルの併用時にお...2NaN単一群非盲検...single assignmenttreatment purpose(1) Patients who are 18 years old over (at the...(1) Patients with concomitant or pre-existing ...18age old overNo limitBothNaNNaN(TM5614)\\r\\nTM5614 should be taken orally afte...
875jRCT2031210299NaNNaN再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験再発悪性神経膠腫再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...1NaN単一群非盲検...single assignmenttreatment purpose1.\\tEstimated life expectancy >= 3 months\\r\\n2...1.\\tPrior therapy with bevacizumab or other an...18age old overNo limitBothNaNNaNPatients will receive DSP-0390 orally once dai...
981jRCT2031200153NaNNaNCellm-001による初発膠芽腫治療効果無作為比較対照試験膠芽腫脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...3NaN無作為化比較二重盲検...parallel assignmenttreatment purpose(1) 18 years old or older and 75 years old or ...(1) Systemic administration of corticosteroids...18age old over75age old underBothNaNNaNInject the investigational drug (Cellm-001 or ...
\n", "

11 rows × 38 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "67 jRCT2051240150 NCT06622941 NaN \n", "103 jRCT2051240121 NCT06413706 NaN \n", "224 jRCT2031240090 NaN NaN \n", "286 jRCT2071230124 NCT06541665 NaN \n", "321 jRCT2071230114 NCT06240741 NaN \n", "338 jRCT2041230136 NaN NaN \n", "349 jRCT2032230554 NaN NaN \n", "473 jRCT2051230069 NaN NaN \n", "476 jRCT2021230016 NaN NaN \n", "875 jRCT2031210299 NaN NaN \n", "981 jRCT2031200153 NaN NaN \n", "\n", " Title Target \\\n", "67 ONO-4538-126：ラブドイド腫瘍を対象としたONO-4538 の有効性及び安全性を検... ラブドイド腫瘍 \n", "103 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... 悪性神経膠腫 \n", "224 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... 悪性神経膠腫 \n", "286 ONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40... 中枢神経系原発リンパ腫 \n", "321 日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを... 神経内分泌腫瘍（NEN） \n", "338 再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験 再発膠芽腫 \n", "349 初発膠芽腫に対する新型高出力中性子線源を用いた加速器BNCT装置iBNCT001及びSPM-... 初発膠芽腫 \n", "473 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 神経膠腫 \n", "476 皮膚血管肉腫に対するパクリタキセルとTM5614併用の安全性・有効性を検討する第Ⅱ相医師主導治験 皮膚血管肉腫 \n", "875 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 再発悪性神経膠腫 \n", "981 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 膠芽腫 \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 \\\n", "67 ラブドイド腫瘍を対象としたONO-4538 の有効性及び安全性を検討する 2 NaN \n", "103 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 2 NaN \n", "224 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl... 3 NaN \n", "286 未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及... 1 NaN \n", "321 神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT... 3 NaN \n", "338 再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を... 1 NaN \n", "349 治験機器iBNCT001及び治験薬SPM-011を用いたホウ素中性子捕捉療法（BNCT）に、... 1 NaN \n", "473 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 1 NaN \n", "476 皮膚血管肉腫のパクリタキセル単剤療法無効症例を対象にTM5614とパクリタキセルの併用時にお... 2 NaN \n", "875 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 1 NaN \n", "981 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... 3 NaN \n", "\n", " 無作為化 盲検化 ... assignment purpose \\\n", "67 単一群 非盲検 ... single assignment treatment purpose \n", "103 無作為化比較 非盲検 ... parallel assignment treatment purpose \n", "224 無作為化比較 非盲検 ... parallel assignment treatment purpose \n", "286 単一群 非盲検 ... single assignment treatment purpose \n", "321 単一群 非盲検 ... single assignment diagnostic purpose \n", "338 単一群 非盲検 ... single assignment treatment purpose \n", "349 非無作為化比較 非盲検 ... single assignment other \n", "473 単一群 非盲検 ... single assignment treatment purpose \n", "476 単一群 非盲検 ... single assignment treatment purpose \n", "875 単一群 非盲検 ... single assignment treatment purpose \n", "981 無作為化比較 二重盲検 ... parallel assignment treatment purpose \n", "\n", " Inclusion Criteria \\\n", "67 1. Gender: Not specified\\r\\n2. Age (at the tim... \n", "103 Subjects required to meet all the folloiwng cr... \n", "224 1) Histologically diagnosed as high grade glio... \n", "286 1. Patients diagnosed with PCNSL\\r\\n2. Patient... \n", "321 1. Signed informed consent must be obtained pr... \n", "338 (1) Patients with a histological diagnosis of ... \n", "349 - Karnofsky Performance Status is greater than... \n", "473 \\r\\n All of the following items shal... \n", "476 (1) Patients who are 18 years old over (at the... \n", "875 1.\\tEstimated life expectancy >= 3 months\\r\\n2... \n", "981 (1) 18 years old or older and 75 years old or ... \n", "\n", " Exclusion Criteria Age Minimum \\\n", "67 1. Patients with a history of active concurren... 1age old over \n", "103 Patients who meets any of the following criter... No limit \n", "224 1) Have a history or merger of other malignanc... 18age old over \n", "286 1.Patients with intraocular PCNSL without brai... 18age old over \n", "321 1. Inability to complete the needed investigat... 18age old over \n", "338 (1) Patients with extracerebral metastases.\\r\\... 18age old over \n", "349 - Multiple lesions, bilateral lesions, dissemi... 18age old over \n", "473 \\r\\n1) Active... 18age old over \n", "476 (1) Patients with concomitant or pre-existing ... 18age old over \n", "875 1.\\tPrior therapy with bevacizumab or other an... 18age old over \n", "981 (1) Systemic administration of corticosteroids... 18age old over \n", "\n", " Age Maximum Gender Discontinuation Criteria \\\n", "67 No limit Both NaN \n", "103 21age old not NaN NaN \n", "224 75age old under Both NaN \n", "286 No limit Both NaN \n", "321 No limit Both NaN \n", "338 75age old under Both NaN \n", "349 85age old under Both NaN \n", "473 No limit Both NaN \n", "476 No limit Both NaN \n", "875 No limit Both NaN \n", "981 75age old under Both NaN \n", "\n", " Keyword \\\n", "67 NaN \n", "103 NaN \n", "224 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n", "286 NaN \n", "321 NaN \n", "338 NaN \n", "349 boron, neutron, glioblastoma \n", "473 NaN \n", "476 NaN \n", "875 NaN \n", "981 NaN \n", "\n", " Intervention(s) \n", "67 For adults, Nivolumab (recombinant) is adminis... \n", "103 Drug: Abemaciclib\\r\\nAdministered orally\\r\\nOt... \n", "224 Group A: BPC Therapy\\r\\nDepending on the patie... \n", "286 Concomitant administration of ONO-4059 and rit... \n", "321 [68Ga]Ga-DOTA-TATE will be administered intrav... \n", "338 Dosing frequency: 1 time /week\\r\\nDose Levels\\... \n", "349 - Intravenous administration of investigationa... \n", "473 \\r\\nLomustine 130 mg/m2 orally every ... \n", "476 (TM5614)\\r\\nTM5614 should be taken orally afte... \n", "875 Patients will receive DSP-0390 orally once dai... \n", "981 Inject the investigational drug (Cellm-001 or ... \n", "\n", "[11 rows x 38 columns]" ] }, "execution_count": 57, "metadata": {}, "output_type": "execute_result" } ], "source": [ "matched_df" ] }, { "cell_type": "code", "execution_count": 58, "metadata": {}, "outputs": [ { "data": { "text/plain": [ "['尿路上皮癌',\n", " '切除不能進行・再発胃癌',\n", " '非小細胞肺癌',\n", " '進行性悪性固形癌\\n転移性悪性固形癌',\n", " '肺がん',\n", " '胃腺癌及び食道胃接合部腺癌',\n", " '非扁平上皮非小細胞肺癌',\n", " '未治療の濾胞性リンパ腫',\n", " 'ミスマッチ修復機能欠損（dMMR）又は高頻度マイクロサテライト不安定性（MSI-H）を有する固形がん',\n", " 'MET過剰発現を有する非小細胞肺癌',\n", " '進行／転移性固形癌',\n", " '頭頸部扁平上皮癌',\n", " '転移性膵管腺癌（mPDAC）',\n", " '前立腺癌',\n", " 'トリプルネガティブ乳癌',\n", " 'HR+/HER2-の切除不能局所進行又は転移性乳癌の患者',\n", " '未治療の転移性非扁平上皮非小細胞肺癌（NSCLC）',\n", " 'PD-L1陽性の転移性非小細胞肺癌',\n", " '去勢抵抗性前立腺癌',\n", " '切除不能皮膚血管肉腫',\n", " 'PD-L1陽性の未治療の転移性非小細胞肺癌',\n", " 'NSQ, NSCLC',\n", " '卵巣癌、腹膜癌及び卵管癌',\n", " '進行固形癌',\n", " '進行固形癌',\n", " '進展型小細胞肺癌',\n", " '高リスク大細胞型B細胞リンパ腫',\n", " '子宮体癌',\n", " 'HER2陽性転移性乳癌',\n", " '・進行性固形腫瘍・進行性乳がん・転移性乳がん・ホルモン受容体陽性乳がん・ホルモン受容体陽性乳がん...',\n", " '膵管腺癌\\n非小細胞肺癌\\n大腸癌',\n", " '進行固形がん',\n", " '非小細胞肺癌',\n", " 'ラブドイド腫瘍',\n", " '非小細胞肺癌',\n", " '膵癌',\n", " '非ホジキンリンパ腫',\n", " 'H3 K27M 変異を有する初発びまん性神経膠腫',\n", " '胃癌、胃食道接合部癌',\n", " '局所進行又は再発性の外陰癌・腟癌・子宮頸癌',\n", " '固形癌',\n", " '転移性固形がん\\n進行性固形がん\\n非小細胞肺がん\\nSMARCA4欠損がん',\n", " '卵巣癌\\n子宮内膜癌\\n非小細胞肺癌',\n", " '再発・難治性多発性骨髄腫',\n", " '転移性去勢抵抗性前立腺癌',\n", " 'Up-to-7基準外の中期肝細胞癌',\n", " '進行性非小細胞肺癌（NSCLC）及びその他の固形がん',\n", " '転移性肝臓癌',\n", " '悪性神経膠腫',\n", " '転移性非小細胞肺がん',\n", " '固形がん',\n", " '再発多形性膠芽腫',\n", " '転移性膵管腺癌',\n", " '転移性固形がん\\n再発性固形がん\\n進行性固形がん',\n", " '非小細胞肺癌',\n", " '再発性低悪性度漿液性卵巣癌（LGSOC）',\n", " 'B細胞性非ホジキンリンパ腫\\n- 濾胞性リンパ腫(FL)\\n- びまん性大細胞型B細胞リンパ腫(DLBCL)',\n", " '非小細胞肺癌',\n", " '遠隔転移を伴う結腸・直腸癌',\n", " '進行固形がん',\n", " '肝細胞癌',\n", " '進行又は転移例に対する標準治療による治療歴のあるKRAS G12C陽性進行又は転移性非小細胞肺癌',\n", " '●固形腫瘍',\n", " '進行固形がん',\n", " '非小細胞性肺がん',\n", " '進行性固形癌',\n", " 'B細胞性非ホジキンリンパ腫 (NHL) \\n慢性リンパ性白血病 (CLL)',\n", " '進行非小細胞肺がん',\n", " 'びまん性大細胞型 B 細胞リンパ腫',\n", " '進行固形癌',\n", " '非小細胞肺癌',\n", " 'HER2遺伝子異常を伴う固形腫瘍',\n", " '固形腫瘍',\n", " '子宮頸癌\\n胃/胃食道接合部腺癌\\nマイクロサテライト安定性結腸直腸癌\\n非小細胞肺癌\\n頭頸部扁平上皮癌...',\n", " '胆道癌',\n", " '転移性去勢抵抗性前立腺癌',\n", " 'HER2陽性の進行性又は転移性の胆道癌',\n", " '進行期乳房外パジェット病',\n", " '多発性骨髄腫',\n", " '転移性去勢抵抗性前立腺癌',\n", " '非小細胞肺癌',\n", " '濾胞性リンパ腫',\n", " '非小細胞肺癌',\n", " '未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通常型軟骨肉腫',\n", " '標準治療がない、または標準治療に不応もしくは不耐の根治切除不能な進行・再発固形がん患者',\n", " '扁平上皮非小細胞肺癌',\n", " '子宮頸癌',\n", " '非小細胞肺癌',\n", " '大細胞型B細胞リンパ腫',\n", " '非ホジキンリンパ腫\\n難治性B細胞性非ホジキンリンパ腫\\n再発B細胞性非ホジキンリンパ腫',\n", " '多発性骨髄腫、慢性骨髄性白血病',\n", " 'HER2発現を有する固形癌',\n", " '限局型小細胞肺癌',\n", " '結腸直腸癌、膵管腺癌、胆道癌',\n", " '\"再発又は難治性の多発性骨髄腫\\n治療歴のあるアミロイド軽鎖（AL）アミロイドーシス\"',\n", " '固形癌',\n", " '進行性又は転移性非扁平上皮非小細胞肺癌',\n", " '未治療のFLIPI 2～5の濾胞性リンパ腫患者',\n", " '再発進行原発性肺腺癌',\n", " '臨床病期II期またはIII期と診断され、かつ切除可能な乳癌',\n", " '臨床病期II期またはIII期と診断され、かつ切除可能な乳癌',\n", " '乳がん',\n", " '食道癌（扁平上皮癌）',\n", " '多発性骨髄腫',\n", " '非小細胞肺癌',\n", " '胃腺癌、食道胃接合部腺癌及び食道腺癌',\n", " '転移性乳癌（mBC）及び進行または転移性胃又は胃食道接合部又は食道腺癌（mGEAC）患者',\n", " '進展型小細胞肺癌\\n小細胞肺癌',\n", " '非小細胞肺癌',\n", " '進行固形癌',\n", " '筋層非浸潤性膀胱癌',\n", " '非小細胞肺癌',\n", " '去勢抵抗性前立腺癌',\n", " '進行乳癌',\n", " '進展型小細胞肺癌',\n", " '悪性神経膠腫',\n", " '転移性固形がん\\n再発性固形がん\\n進行性固形がん',\n", " '成人T細胞白血病・リンパ腫',\n", " '子宮体がん',\n", " '非小細胞肺癌',\n", " '進行小細胞肺癌',\n", " '卵巣癌・固形がん',\n", " '転移性結腸直腸癌',\n", " '未治療の転移性非扁平上皮非小細胞肺癌（NSCLC）',\n", " '筋層非浸潤性膀胱癌',\n", " '子宮体癌',\n", " '転移性前立腺癌',\n", " '転移性前立腺癌',\n", " '再発又は難治性の多発性骨髄腫',\n", " '肺がん、食道がん、胃癌等の固形がん',\n", " '子宮内膜癌、頭頸部扁平上皮癌、膵管腺癌、大腸癌、肝細胞癌、食道腺癌／食道胃接合部腺癌／胃腺癌、尿...',\n", " '多発性骨髄腫',\n", " '成人T細胞白血病リンパ腫',\n", " '再発又は難治性の多発性骨髄腫',\n", " 'HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌',\n", " '進行固形がん',\n", " '子宮体癌',\n", " '悪性胸膜中皮腫',\n", " '乳癌',\n", " '非小細胞肺癌',\n", " '進行固形癌',\n", " '固形癌',\n", " '中枢神経系原発リンパ腫',\n", " '慢性リンパ性白血病／小リンパ球性リンパ腫',\n", " '悪性黒色腫',\n", " '再発小細胞肺癌',\n", " '進行NSCLC 及びその他の固形がん',\n", " 'ホルモン受容体（HR）陽性ヒト上皮増殖因子受容体2（HER2）陰性の進行または転移乳癌',\n", " '扁平上皮非小細胞肺がん',\n", " '転移性非扁平上皮非小細胞肺癌',\n", " '固形腫瘍及び血液学的悪性腫瘍',\n", " '非小細胞肺癌',\n", " '進行性又は転移性の固形がん',\n", " 'エストロゲン受容体陽性／ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌',\n", " '未治療の大細胞型B細胞リンパ腫患者',\n", " '多発性骨髄腫',\n", " '乳癌',\n", " '固形がん',\n", " '局所進行（切除不能）及び／又は遠隔転移を伴うHER2発現癌',\n", " '多発性骨髄腫',\n", " '再発小細胞肺癌（SCLC）',\n", " '神経内分泌腫瘍（NEN）',\n", " '固形癌',\n", " '組織学的又は細胞学的に確認されたES-SCLC',\n", " '再発又は難治性濾胞性リンパ腫',\n", " 'CIでM1のないPSMA-PETによるオリゴ転移性前立腺がん（OMPC）',\n", " '再発・難治性のマントル細胞リンパ腫又は再発・難治性の前駆B細胞性急性リンパ芽球性白血病',\n", " '再発または難治性多発性骨髄腫',\n", " '多発性骨髄腫',\n", " '限局型小細胞肺癌\\n小細胞肺癌',\n", " '本治験の被験者は，アジアの実施医療機関から参加する，確立された治療が無効である又はその適応ではな...',\n", " '再発膠芽腫',\n", " '局所進行又は転移性固形癌',\n", " '局所進行頭頸部扁平上皮癌',\n", " 'MTAP 欠損固形がん患者',\n", " '古典的ホジキンリンパ腫及び非ホジキンリンパ腫',\n", " '胃癌、食道胃接合部癌、膵管腺癌',\n", " '転移性去勢感受性前立腺癌',\n", " '局所進行頭頸部扁平上皮癌',\n", " '初発膠芽腫',\n", " '肝細胞癌，膵管腺癌，胆道癌，食道扁平上皮癌，乳癌，頭頚部扁平上皮癌',\n", " '固形がん',\n", " '多発性骨髄腫',\n", " '手術不能かつ既存治療不応の進行・再発固形がん',\n", " '早期又は進行／転移性の固形がん',\n", " '非小細胞肺癌',\n", " '非小細胞肺癌\\n転移性腫瘍',\n", " '固形癌',\n", " '新生物',\n", " '胆道癌',\n", " '潜在的にSEZ6を発現する進行固形がん',\n", " '肺外神経内分泌癌（ただしメルケル細胞癌，甲状腺髄様癌又はグレード3の神経内分泌腫瘍を除く）\\n肺の大...',\n", " '非小細胞肺癌（NSCLC）',\n", " 'HER2 TKD変異を有する切除不能，局所進行又は転移性非扁平上皮非小細胞肺癌',\n", " '再発又は難治性の多発性骨髄腫（RRMM）',\n", " '多発性骨髄腫',\n", " 'HER2低発現の胃腺癌又は胃食道接合部腺癌又は食道腺癌',\n", " '未治療多発性骨髄腫',\n", " '再発又は難治性のT細胞リンパ腫及び慢性リンパ性白血病/小リンパ球性リンパ腫',\n", " '消化器（消化管・肝胆膵）神経内分泌癌',\n", " '直腸がん',\n", " '切除不能な胸膜中皮腫',\n", " '乳がん、早期乳がん',\n", " '切除不能な転移性結腸・直腸癌',\n", " '悪性固形腫瘍',\n", " '局所進行子宮頸癌',\n", " '遠隔転移を有する膵がん',\n", " '• パート1: 局所進行又は転移性固形癌\\n• パート2: 胃腺癌、食道胃接合部腺癌、食道腺癌又は非小細胞肺癌',\n", " '非小細胞肺癌',\n", " '進行性又は転移性がん',\n", " '再発及び難治性の多発性骨髄腫',\n", " '大細胞型B細胞性リンパ腫、濾胞性リンパ腫',\n", " '進行性又は転移性の固形がん、進行性又は転移性の食道癌、進行性又は転移性の頭頸部扁平上皮癌',\n", " '再発又は遠隔転移を有する頭頸部癌',\n", " '再発又は難治性のT細胞リンパ腫',\n", " '急性白血病（慢性白血病の急性転化例を含む）、悪性リンパ腫\\nただし、L-アスパラギナーゼ製剤に過敏症...',\n", " '黒色腫',\n", " '固形がん（Arm 1）、非小細胞肺癌（Arm 2及びArm 3）',\n", " 'EGFRのエクソン20挿入変異を有する局所進行又は転移性非扁平上皮非小細胞肺癌',\n", " 'EGFRのエクソン20挿入変異及びUncommon/Single又はCompound変異を有する局所進行又は転移性非小細胞肺癌',\n", " '用量漸増部分：組織型を問わず，KRAS wt増幅又はKRAS G12V変異を有する治療選択肢が限られている固形癌...',\n", " 'B細胞性非ホジキンリンパ腫',\n", " '再発若しくは転移性又は切除不能な局所進行の有棘細胞癌',\n", " '胃腺がん, 胃食道接合部(GEJ)腺がん',\n", " '前立腺癌',\n", " '臨床的に遠隔転移のない膵がん',\n", " '癌関連静脈血栓塞栓症',\n", " '尿路上皮癌',\n", " 'CRPCコホート\\n転移性去勢抵抗性前立腺癌',\n", " '標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん',\n", " 'KRAS wt増幅を有する固形癌（GAC，EAC，及びGEJAC）\\n組織型を問わず，KRAS wt増幅又はKRAS G12V変異を...',\n", " '癌',\n", " '中枢神経系原発悪性リンパ腫',\n", " '肝細胞癌、胆道癌',\n", " 'エストロゲン受容体陽性／ヒト上皮増殖因子受容体2陰性の進行乳癌',\n", " '血液がん',\n", " '筋層浸潤性膀胱癌',\n", " 'びまん性大細胞型B細胞リンパ腫 ',\n", " '非小細胞肺癌',\n", " '神経膠腫',\n", " '局所進行、転移性、又は切除不能な固形癌',\n", " '皮膚血管肉腫',\n", " '局所進行又は転移性固形がん',\n", " '胆道癌',\n", " '固形癌',\n", " '多発性骨髄腫',\n", " '多発性骨髄腫',\n", " '結腸癌',\n", " '胃癌\\n食道胃接合部癌\\n膵臓線癌\\n食道線癌',\n", " '進行切除不能肝細胞癌',\n", " '頭頸部癌',\n", " '卵巣癌',\n", " '胃腺癌、胃食道接合部（GEJ）腺癌、及び食道腺癌を含む進行性又は転移性GEA患者',\n", " '筋層非浸潤性膀胱癌',\n", " '未治療の切除不能または再発胸腺癌',\n", " '乳癌',\n", " '局所進行又は転移性非扁平上皮非小細胞肺癌',\n", " '膀胱がん\\n転移性腫瘍\\n尿管癌',\n", " '再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん',\n", " '乳がん、早期乳がん',\n", " '進行性の切除不能又は転移性MSIhi 又はdMMR固形がん，結腸直腸がん（CRC）',\n", " '多発性骨髄腫',\n", " '固形癌',\n", " '局所進行切除不能又は転移性の胃腺癌又は食道胃接合部腺癌',\n", " 'IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）',\n", " 'トリプルネガティブ乳がん',\n", " 'EGFR遺伝子変異を有する非小細胞肺癌患者',\n", " 'FGFR2遺伝子融合又は再構成を伴う胆管癌',\n", " '非小細胞肺癌',\n", " '多発性骨髄腫',\n", " '低悪性度神経膠腫、膵癌',\n", " '進行固形癌、非小細胞肺癌、頭頚部腫瘍',\n", " '固形がん',\n", " '卵巣癌',\n", " '肝転移を有する進行又は再発固形癌の患者',\n", " 'DLL3を発現する小細胞肺癌及びその他の神経内分泌腫瘍',\n", " '卵巣扁平上皮癌',\n", " '進行性固形がん',\n", " 'BRAF V600変異を有する局所進行切除不能又は転移性黒色腫、治療歴のないBRAF V600E変異を有する転移性結...',\n", " '進行又は転移性固形がん',\n", " '肝細胞癌',\n", " '食道がん、胃がん',\n", " 'エストロゲン受容体陽性／ヒト上皮増殖因子受容体2陰性の進行乳癌',\n", " 'LTK融合遺伝子陽性の進行非小細胞肺癌（NSCLC）',\n", " '多発性骨髄腫患者',\n", " '進行，切除不能又は転移性固形癌',\n", " '食道扁平上皮癌',\n", " '再発又は難治性多発性骨髄腫',\n", " '固形癌',\n", " 'HER2 陽性転移性結腸直腸癌',\n", " '乳癌',\n", " 'がん悪液質',\n", " '切除不能胆道癌',\n", " '進行性尿路上皮癌',\n", " '多発性骨髄腫',\n", " '二次性中枢神経系リンパ腫',\n", " '小細胞肺癌及びその他の神経内分泌癌',\n", " 'ミスマッチ修復異常を認める切除可能なStage II/III およびStage I 直腸癌',\n", " '局所進行頭頸部扁平上皮癌',\n", " '用量漸増コホート：固形がん\\n拡大コホート1：結腸・直腸がん\\n拡大コホート2：TMEM180陽性の結腸・直腸...',\n", " '膀胱新生物受容体、線維芽細胞増殖因子',\n", " '初発の多発性骨髄腫',\n", " '切除不能進行・再発胃癌',\n", " '非小細胞肺癌',\n", " '乳房外パジェット病',\n", " '頭頸部がんのがん治療に伴う口腔粘膜炎の疼痛 ',\n", " '非小細胞肺癌',\n", " '非小細胞肺癌',\n", " '子宮体癌\\n胃癌\\n転移性去勢抵抗性前立腺癌\\n卵巣癌\\n大腸癌\\n尿路上皮癌\\n胆道癌',\n", " '特定の進行固形癌',\n", " '結腸・直腸癌遠隔転移の治癒切除を予定している患者',\n", " '成熟B細胞性リンパ腫',\n", " '非小細胞肺癌',\n", " '多発性骨髄腫',\n", " '再発及び／又は難治性B細胞性非ホジキンリンパ腫（B-NHL）及び再発及び／又は難治性B細胞性急性リンパ芽...',\n", " '結腸直腸癌',\n", " '固形がん',\n", " '固形癌',\n", " '・肉腫、ユーイング 、・新生物転移',\n", " '進行非小細胞肺がん',\n", " '乳がん',\n", " '原発性直腸癌',\n", " '進行非小細胞肺がん\\nEGFR変異\\nHER2変異',\n", " '肝細胞癌',\n", " '卵巣がん',\n", " '非小細胞肺癌 ',\n", " '多発性骨髄腫',\n", " '悪性腹水を伴うMSS進行期消化器癌',\n", " '固形がん',\n", " '腹膜播種を伴う大腸癌',\n", " '固形癌',\n", " '標準治療不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍',\n", " '進行腎細胞癌及び卵巣癌',\n", " '悪性胸膜中皮腫',\n", " '移植後の初発多発性骨髄腫',\n", " '肝細胞癌',\n", " '胃癌又は食道胃接合部癌',\n", " '非小細胞肺癌',\n", " '局所進行（切除不能）又は転移性乳癌',\n", " '進行固形癌',\n", " 'BRAF V600E 変異を有する切除可能大腸癌遠隔転移患者',\n", " '進行MTAP欠損固形癌',\n", " 'EGFR 遺伝子変異陽性未治療進行非小細胞肺癌',\n", " '肺扁平上皮癌',\n", " '標準治療がない、あるいは標準的治療法に不応又は不耐の固形癌',\n", " 'Nectin-4陽性固形癌',\n", " '非小細胞肺癌',\n", " '胃癌、食道胃接合部癌',\n", " '筋層浸潤性膀胱癌',\n", " '進行固形癌',\n", " '切除不能な局所進行非小細胞肺癌（ステージIII）',\n", " '胃腺癌，食道胃接合部腺癌，膵腺癌',\n", " '多発性骨髄腫',\n", " '非小細胞肺癌を除くALK 融合遺伝子陽性、進行・再発の固形腫瘍',\n", " '再発又は難治性のB細胞性非ホジキンリンパ腫',\n", " 'PD-L1高発現（TPSが50%以上）の進行又は転移性非小細胞肺癌',\n", " 'びまん性大細胞リンパ腫、急性リンパ芽球性白血病、慢性リンパ性白血病',\n", " '乳癌、胆道癌、卵巣癌、子宮内膜癌',\n", " '固形癌',\n", " '進行性又は転移性の固形がん',\n", " '前立腺癌',\n", " 'HER2エクソン19又は20の変異を有する非小細胞肺癌',\n", " '固形がん',\n", " 'NRG1融合が記録されているNSCLC、膵腺癌、および他のすべての固形腫瘍',\n", " '悪性胸膜中皮腫',\n", " '中間期肝細胞癌',\n", " '局所進行又は転移性固形がん',\n", " '消化管間質腫瘍',\n", " '転移性又は切除不能の悪性黒色腫, 転移性又は切除不能の肝細胞癌, 転移性又は切除不能の大腸癌',\n", " '非小細胞肺癌，進行固形癌，胃食道接合部腺癌，大腸癌',\n", " '肺扁平上皮癌',\n", " '非小細胞肺癌（NSCLC），頭頸部扁平上皮癌（HNSCC），その他の固形癌',\n", " '進行・再発非小細胞肺癌',\n", " '非小細胞肺癌（NSCLC）',\n", " '乳がん',\n", " '中皮腫，NF2 / LATS1 / LATS2 変異を伴う腫瘍，及び機能獲得性YAP / TAZ融合を伴う腫瘍を有する患者',\n", " 'HER2陽性の胃癌または胃食道接合部癌',\n", " '再発悪性神経膠腫',\n", " '固形癌',\n", " '上皮性卵巣がん（原発性腹膜がん及び卵管がんを含む）',\n", " '非小細胞肺癌、大腸新生物、子宮内膜新生物、卵巣新生物、膵臓新生物、胆道新生物',\n", " '【コホートA】BRCA変異陽性の子宮平滑筋肉腫：募集中\\n【コホートB】BRCA変異陰性・HRD陽性の子宮平滑筋...',\n", " '未治療の治癒切除不能な膵がん患者（ 遠隔転移例・切除不能局所進行膵がん）を対象とし、術後の再発症例...',\n", " '成人のROS1 融合遺伝子陽性の進行または転移性非小細胞肺癌(NSCLC)患者',\n", " '転移性食道扁平上皮癌',\n", " '多発性骨髄腫',\n", " '進行固形がん',\n", " '再発又は難治性の多発性骨髄腫（RRMM）',\n", " '胃癌',\n", " '進行固形癌',\n", " '・進行固形癌 \\n・KRAS p.G12C変異を有する',\n", " 'LK、ROS1またはNTRK1-3の遺伝子再構成を有する進行固形癌患者',\n", " '筋層非浸潤性膀胱がん',\n", " '固形がん及び血液がん（AML, MDS, DLBCL）',\n", " '成人 T 細胞白血病・リンパ腫',\n", " 'ER陽性HER2陰性乳癌',\n", " '進行固形癌',\n", " '筋層浸潤性膀胱癌',\n", " '進行又は転移性非小細胞肺癌',\n", " '再発又は難治性の大細胞型B細胞リンパ腫',\n", " 'GPC3発現手術不能進行再発卵巣明細胞癌で腹膜播種を有する患者',\n", " '筋層非浸潤性膀胱癌',\n", " '前立腺がん',\n", " '非ホジキンリンパ腫 （びまん性大細胞型B細胞リンパ腫）',\n", " '膀胱癌',\n", " '表在性食道癌',\n", " '多発性骨髄腫',\n", " '膵臓がん',\n", " '局所進行または転移性ER陽性HER2陰性乳癌，局所進行または転移性去勢抵抗性前立腺癌，局所進行または転...',\n", " '頭頸部扁平上皮がん',\n", " '固形癌（非小細胞肺癌など）',\n", " '胃腺癌、胃食道接合部腺癌又は食道腺癌',\n", " '膠芽腫',\n", " '4型進行胃癌',\n", " '悪性黒色腫',\n", " '進行性悪性黒色腫']" ] }, "execution_count": 58, "metadata": {}, "output_type": "execute_result" } ], "source": [ "target_list" ] }, { "cell_type": "code", "execution_count": 61, "metadata": {}, "outputs": [], "source": [ "with open('test.txt', 'w') as f:\n", " print(target_list, file=f)" ] }, { "cell_type": "code", "execution_count": 70, "metadata": {}, "outputs": [], "source": [ "# Target列を分割する関数\n", "def split_target(target):\n", " # 指定された区切り文字で分割\n", " split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n", " # 空白文字を除外してリストとして返す\n", " return [word.strip() for word in split_words if word.strip()]" ] }, { "cell_type": "code", "execution_count": 73, "metadata": {}, "outputs": [ { "data": { "text/plain": [ "['PD-L1高発現（TPSが50%以上）の進行', '転移性非小細胞肺癌', '神経膠腫']" ] }, "execution_count": 73, "metadata": {}, "output_type": "execute_result" } ], "source": [ "split_target('PD-L1高発現（TPSが50%以上）の進行・転移性非小細胞肺癌、神経膠腫')" ] }, { "cell_type": "code", "execution_count": 74, "metadata": {}, "outputs": [], "source": [ "# Target列を分割してTargetWord列を追加\n", "basedf['TargetWord'] = basedf['Target'].apply(split_target)\n" ] }, { "cell_type": "code", "execution_count": 75, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTarget研究・治験の目的試験等のフェーズ試験の種類無作為化盲検化...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWord
0jRCT2021240039NCT06632951NaN[M25-204]転移性尿路上皮癌患者を対象に，livmoniplimab とbudigal...尿路上皮癌主要目的：全生存期間（以下「OS」）を指標として，livmoniplimab と budig...2NaN無作為化比較非盲検...treatment purpose-Participant has histologically or cytological...-Participant has received more than 1 prior ch...18age old overNo limitBothNaNNaN-Arm 1: Livmoniplimab (Dose A) + Budigalimab\\r...[尿路上皮癌]
4jRCT2031240512NaNNaNフッ化ピリミジン製剤及びプラチナ製剤を含む一次治療に不応・不耐となった切除不能進行・再発胃癌...切除不能進行・再発胃癌フッ化ピリミジン・プラチナ系薬剤に不応・不耐の切除不能進行・再発胃癌被験者を対象として、ベバ...1NaN無作為化比較非盲検...treatment purpose1)\\tAge between 18 and 75 years.\\r\\n2)\\tPerfor...1)\\tPrior treatment history with paclitaxel, r...18age old over75age old underBothNaNNaNSafety Part (Dose Escalation):\\r\\nLevel 0: Bev...[切除不能進行, 再発胃癌]
7jRCT2051240197NCT06692738NaNPD-L1 陽性の転移性扁平上皮非小細胞肺癌患者に対する一次治療として、Rilvegosto...非小細胞肺癌Treatment3NaN無作為化比較二重盲検...treatment purpose- Histologically or cytologically documented s...- Presence of small cell and neuroendocrine hi...18age old overNo limitBothNaNNaNParticipants will be randomized in a 1:1 ratio...[非小細胞肺癌]
8jRCT2031240508NCT06573294NaN悪性固形癌患者を対象にGEN1057の安全性及び抗腫瘍活性を評価するヒト初回投与、非盲検、用...進行性悪性固形癌\\n転移性悪性固形癌本第I相試験の目的は、転移性又は進行性病変を有する悪性固形癌患者を対象に、GEN1057を単...1NaN単一群非盲検...treatment purpose-Advanced and/or metastatic solid tumors, who ...Has been exposed to any of the following prior...18age old overNo limitBothNaNNaNGEN1057 monotherapy will be administered intra...[進行性悪性固形癌, 転移性悪性固形癌]
12jRCT2041240130NaNNaN中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...肺がん全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...2NaN無作為化比較非盲検...treatment purpose(1) Patients scheduled to undergo anatomical l...(1) Patients with a history of allergy to the ...18age old overNo limitBothNaNNaNTreatment group\\r\\nAdminister GRA 1mg intraven...[肺がん]
..................................................................
974jRCT2031200203NCT04379596NaNHER2発現の成人胃癌患者を対象としてトラスツズマブ デルクステカン（T-DXd）の単剤療法...胃腺癌、胃食道接合部腺癌又は食道腺癌DESTINY-Gastric03は、HER2発現の進行・転移性胃癌・胃食道接合部（GEJ）...1-2NaN無作為化比較非盲検...treatment purpose1. Male and female participants must be at lea...1. History of active primary immunodeficiency,...18age old over130age old underBothNaNNaNExperimental: Arm 1A: T-DXd and 5-fluorouracil...[胃腺癌, 胃食道接合部腺癌, 食道腺癌]
981jRCT2031200153NaNNaNCellm-001による初発膠芽腫治療効果無作為比較対照試験膠芽腫脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...3NaN無作為化比較二重盲検...treatment purpose(1) 18 years old or older and 75 years old or ...(1) Systemic administration of corticosteroids...18age old over75age old underBothNaNNaNInject the investigational drug (Cellm-001 or ...[膠芽腫]
996jRCT2031200087NaNNaN4型進行胃癌に対する術後または周術期補助化学療法としての全身・腹腔内併用化学療法と全身化学療...4型進行胃癌術後腹膜播種のリスクが高い4型進行胃癌を対象として、全身・腹腔内併用化学療法の全身化学療法に...3NaN無作為化比較非盲検...treatment purposeConfirmation before temporary registration\\r\\n...1)\\tSimultaneously active double cancer.\\r\\n2)...20age old over75age old underBothNaNNaNS-1 monotherapy\\r\\noral S-1 80 mg/m2/day on da...[4型進行胃癌]
1053jRCT2033190086NaNNaN悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...悪性黒色腫第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...1-2NaN単一群非盲検...treatment purpose(Phase 1)\\r\\n1) Histologically confirmed malig...(Phase 1 and 2)\\r\\n1) Patients who have brain ...20age old overNo limitBothNaNmalignamt melanoma, advanced stageTest drug (T-hIL12) will be administered into ...[悪性黒色腫]
1067jRCT2051190009NCT03818893JapicCTI-194618進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...進行性悪性黒色腫抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...1-2NaN非無作為化比較非盲検...treatment purposeInclusion criteria \\r\\nPatients meeting all of...Exclusion criteria\\r\\nPatients meeting any of ...20age old over86age old notBothNaNadvanced melanomacombination therapy of intracutaneous GEN0101 ...[進行性悪性黒色腫]
\n", "

416 rows × 39 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "0 jRCT2021240039 NCT06632951 NaN \n", "4 jRCT2031240512 NaN NaN \n", "7 jRCT2051240197 NCT06692738 NaN \n", "8 jRCT2031240508 NCT06573294 NaN \n", "12 jRCT2041240130 NaN NaN \n", "... ... ... ... \n", "974 jRCT2031200203 NCT04379596 NaN \n", "981 jRCT2031200153 NaN NaN \n", "996 jRCT2031200087 NaN NaN \n", "1053 jRCT2033190086 NaN NaN \n", "1067 jRCT2051190009 NCT03818893 JapicCTI-194618 \n", "\n", " Title Target \\\n", "0 [M25-204]転移性尿路上皮癌患者を対象に，livmoniplimab とbudigal... 尿路上皮癌 \n", "4 フッ化ピリミジン製剤及びプラチナ製剤を含む一次治療に不応・不耐となった切除不能進行・再発胃癌... 切除不能進行・再発胃癌 \n", "7 PD-L1 陽性の転移性扁平上皮非小細胞肺癌患者に対する一次治療として、Rilvegosto... 非小細胞肺癌 \n", "8 悪性固形癌患者を対象にGEN1057の安全性及び抗腫瘍活性を評価するヒト初回投与、非盲検、用... 進行性悪性固形癌\\n転移性悪性固形癌 \n", "12 中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr... 肺がん \n", "... ... ... \n", "974 HER2発現の成人胃癌患者を対象としてトラスツズマブ デルクステカン（T-DXd）の単剤療法... 胃腺癌、胃食道接合部腺癌又は食道腺癌 \n", "981 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 膠芽腫 \n", "996 4型進行胃癌に対する術後または周術期補助化学療法としての全身・腹腔内併用化学療法と全身化学療... 4型進行胃癌 \n", "1053 悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第... 悪性黒色腫 \n", "1067 進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体... 進行性悪性黒色腫 \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 \\\n", "0 主要目的：全生存期間（以下「OS」）を指標として，livmoniplimab と budig... 2 NaN \n", "4 フッ化ピリミジン・プラチナ系薬剤に不応・不耐の切除不能進行・再発胃癌被験者を対象として、ベバ... 1 NaN \n", "7 Treatment 3 NaN \n", "8 本第I相試験の目的は、転移性又は進行性病変を有する悪性固形癌患者を対象に、GEN1057を単... 1 NaN \n", "12 全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro... 2 NaN \n", "... ... ... ... \n", "974 DESTINY-Gastric03は、HER2発現の進行・転移性胃癌・胃食道接合部（GEJ）... 1-2 NaN \n", "981 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... 3 NaN \n", "996 術後腹膜播種のリスクが高い4型進行胃癌を対象として、全身・腹腔内併用化学療法の全身化学療法に... 3 NaN \n", "1053 第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ... 1-2 NaN \n", "1067 抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010... 1-2 NaN \n", "\n", " 無作為化 盲検化 ... purpose \\\n", "0 無作為化比較 非盲検 ... treatment purpose \n", "4 無作為化比較 非盲検 ... treatment purpose \n", "7 無作為化比較 二重盲検 ... treatment purpose \n", "8 単一群 非盲検 ... treatment purpose \n", "12 無作為化比較 非盲検 ... treatment purpose \n", "... ... ... ... ... \n", "974 無作為化比較 非盲検 ... treatment purpose \n", "981 無作為化比較 二重盲検 ... treatment purpose \n", "996 無作為化比較 非盲検 ... treatment purpose \n", "1053 単一群 非盲検 ... treatment purpose \n", "1067 非無作為化比較 非盲検 ... treatment purpose \n", "\n", " Inclusion Criteria \\\n", "0 -Participant has histologically or cytological... \n", "4 1)\\tAge between 18 and 75 years.\\r\\n2)\\tPerfor... \n", "7 - Histologically or cytologically documented s... \n", "8 -Advanced and/or metastatic solid tumors, who ... \n", "12 (1) Patients scheduled to undergo anatomical l... \n", "... ... \n", "974 1. Male and female participants must be at lea... \n", "981 (1) 18 years old or older and 75 years old or ... \n", "996 Confirmation before temporary registration\\r\\n... \n", "1053 (Phase 1)\\r\\n1) Histologically confirmed malig... \n", "1067 Inclusion criteria \\r\\nPatients meeting all of... \n", "\n", " Exclusion Criteria Age Minimum \\\n", "0 -Participant has received more than 1 prior ch... 18age old over \n", "4 1)\\tPrior treatment history with paclitaxel, r... 18age old over \n", "7 - Presence of small cell and neuroendocrine hi... 18age old over \n", "8 Has been exposed to any of the following prior... 18age old over \n", "12 (1) Patients with a history of allergy to the ... 18age old over \n", "... ... ... \n", "974 1. History of active primary immunodeficiency,... 18age old over \n", "981 (1) Systemic administration of corticosteroids... 18age old over \n", "996 1)\\tSimultaneously active double cancer.\\r\\n2)... 20age old over \n", "1053 (Phase 1 and 2)\\r\\n1) Patients who have brain ... 20age old over \n", "1067 Exclusion criteria\\r\\nPatients meeting any of ... 20age old over \n", "\n", " Age Maximum Gender Discontinuation Criteria \\\n", "0 No limit Both NaN \n", "4 75age old under Both NaN \n", "7 No limit Both NaN \n", "8 No limit Both NaN \n", "12 No limit Both NaN \n", "... ... ... ... \n", "974 130age old under Both NaN \n", "981 75age old under Both NaN \n", "996 75age old under Both NaN \n", "1053 No limit Both NaN \n", "1067 86age old not Both NaN \n", "\n", " Keyword \\\n", "0 NaN \n", "4 NaN \n", "7 NaN \n", "8 NaN \n", "12 NaN \n", "... ... \n", "974 NaN \n", "981 NaN \n", "996 NaN \n", "1053 malignamt melanoma, advanced stage \n", "1067 advanced melanoma \n", "\n", " Intervention(s) TargetWord \n", "0 -Arm 1: Livmoniplimab (Dose A) + Budigalimab\\r... [尿路上皮癌] \n", "4 Safety Part (Dose Escalation):\\r\\nLevel 0: Bev... [切除不能進行, 再発胃癌] \n", "7 Participants will be randomized in a 1:1 ratio... [非小細胞肺癌] \n", "8 GEN1057 monotherapy will be administered intra... [進行性悪性固形癌, 転移性悪性固形癌] \n", "12 Treatment group\\r\\nAdminister GRA 1mg intraven... [肺がん] \n", "... ... ... \n", "974 Experimental: Arm 1A: T-DXd and 5-fluorouracil... [胃腺癌, 胃食道接合部腺癌, 食道腺癌] \n", "981 Inject the investigational drug (Cellm-001 or ... [膠芽腫] \n", "996 S-1 monotherapy\\r\\noral S-1 80 mg/m2/day on da... [4型進行胃癌] \n", "1053 Test drug (T-hIL12) will be administered into ... [悪性黒色腫] \n", "1067 combination therapy of intracutaneous GEN0101 ... [進行性悪性黒色腫] \n", "\n", "[416 rows x 39 columns]" ] }, "execution_count": 75, "metadata": {}, "output_type": "execute_result" } ], "source": [ "basedf" ] }, { "cell_type": "code", "execution_count": null, "metadata": {}, "outputs": [], "source": [] } ], "metadata": { "kernelspec": { "display_name": "gradio", "language": "python", "name": "python3" }, "language_info": { "codemirror_mode": { "name": "ipython", "version": 3 }, "file_extension": ".py", "mimetype": "text/x-python", "name": "python", "nbconvert_exporter": "python", "pygments_lexer": "ipython3", "version": "3.12.3" } }, "nbformat": 4, "nbformat_minor": 2 }